Obamacare enrollments in health insurance exchanges for the 2025 enrollment period have reached 24.2M, an all-time high. Read ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing ...
The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), has ...
The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration.
CMS has named 15 additional prescription drugs, including diabetes medication Ozempic, for price negotiations under the Inflation Reduction Act. This marks the second round of negotiations aimed at ...
The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, ...
The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare Part D drugs selected for the ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...
Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback